Tagged Articles

Novo Nordisk 48 articles

Novo Nordisk recalls insulin pens

Novo Nordisk is recalling insulin cartridge holders used in some NovoPen insulin pen devices distributed in the U.S. because the holders may crack or break if exposed to certain chemicals such as cleaning agents. Using a cracked or broken cartridge holder could cause the pen to deliver a smaller dose of insulin that intended, which could lead to high blood sugar and potential health problems. The affected batches were distributed between Aug. 1, 2016, and June 22, and have the following batch numbers: EVG1221, EVG1226, FVG7149, FVG7458, FVG8134, FVG8135. Novo Nordisk has received numerous complaints of damaged cartridge holders and ... Read More

FDA approves two new combination type 2 diabetes treatments

Two new treatments for type 2 diabetes were approved by the Food and Drug Administration (FDA), and both contain a combination of the same types of medications – an anti-diabetic drug from the GLP-1 receptor class, and a long-acting insulin. The approvals for both Sanofi’s LixiLan and Novo Nordisk’s IDegLira, were delayed for three months after being recommended for approval by FDA advisory panels last May. LixLan’s approval in the U.S. is its first worldwide for the combination treatment, which includes the GLP-1 receptor agonist lixisenatide (Lyxumia/Adlyxin)and the insulin glargine (Lantus). It is intended for patients with type 2 diabetes ... Read More

Novo Nordisk recalls defective diabetic insulin syringes

Novo Nordisk Inc., is recalling six batches of the GlucaGen HypoKit in the U.S. due to two customer complaints from the U.K. and Portugal involving detached needles on the syringe with Sterile Water for Injection. GlucaGen HypoKit is used to treat severe hypoglycemia (low blood sugar) in patients with diabetes who use insulin. Patients are unable to use syringes with detached needles and could be unable to receive treatment during a hypoglycemic episode. If left untreated, hypoglycemia can eventually lead to unconsciousness and seizures, which can prove fatal. If the blood glucose levels are not quickly restored, continuing hypoglycemia can ... Read More

Victoza heart risk data expected this year

Drug maker Novo Nordisk is weighing its options for releasing data from an important cardiovascular risk study involving its Type 2 diabetes medication Victoza, hoping the drug can show encouraging results in light of the unprecedented success of Eli Lilly and Boehringer Ingelheim’s diabetes drug Jardiance, which showed it cut cardiovascular death in patients by a staggering 32 percent. The Food and Drug Administration (FDA) has ordered manufacturers of newer type 2 diabetes drugs to conduct long-term post marketing studies on their diabetes medications focusing on cardiovascular effects. The ruling came after the agency severely restricted use of the diabetes ... Read More

Victoza claims better efficacy than Invokana

Novo Nordisk is taking great efforts to stretch the profit-earning potential of its blockbuster type 2 diabetes drug Victoza. The company won approval to market the drug as an obesity treatment under the brand name Saxenda, and has launched clinical trials to test the drug as a treatment for nonalcoholic fatty liver disease, one of the most common causes of chronic liver disease. Now the company is taking aim at its competitors in the lucrative diabetes market, rolling out a new meta-analysis showing that Victoza was superior at reducing blood sugar metric HbA1c (a more accurate test for diabetes control) ... Read More

Novo Nordisk could reap billions from experimental diabetes pill

Drug maker Novo Nordisk has enjoyed booming profits from its injectable diabetes treatment Victoza, thanks to winning approval for a potent version of the drug, marketed as Saxenda, as an obesity treatment. But it’s new oral version of a diabetes drug from the same class as Victoza could send profits as high as $20 billion per year. In the pharmaceutical industry, drugs that reap annual profits of at least $1 billion are called blockbusters. There is a special term for a drug that exceeds $10 billion in sales – super-blockbuster, says Seeking Alpha. These drugs are few and far between, ... Read More

Novo Nordisk tests new type 2 diabetes treatment

Drug maker Novo Nordisk’s experimental, once-weekly type 2 diabetes treatment semaglutide is effective at lowering blood sugar levels and triggering weight loss in phase III study participants. However, the drug did have a higher dropout rate – 5 to 6 percent – due to side effects. Semaglutide is a GLP-1 analogue, which is the same class as the diabetes treatments Byetta, Bydureon, and Victoza, the latter of which is also made by Novo Nordisk. Like Byetta, Bydureon and Victoza, semaglutide is administered by injection. Novo Nordisk also has an oral version of semaglutide, which is currently in phase II clinical ... Read More

Victoza fails to improve health in heart failure patients

Novo Nordisk has made great strides to expand the indication of its type 2 diabetes drug Victoza by gaining approval for a high-dose version as a weight loss treatment, marketed as Saxenda. The company is also testing the drug as a treatment for nonalcoholic fatty liver disease. But a new study found the drug ineffective in patients with advanced heart failure. Heart failure is a chronic condition in which the heart does not pump enough blood through the body. About 5 million Americans have heart failure. The study sought to find whether Victoza, known chemically as liraglutide, could correct defects in ... Read More

Diabetes drug tested as treatment for non-alcoholic fatty liver disease

Researchers are testing type 2 diabetes drug Victoza as a possible treatment for non-alcoholic fatty liver disease, the most common form of liver disease in the United States, affecting about 20 percent of the population. The condition describes a wide range of conditions that are caused when fat builds up within the liver. Non-alcoholic steathohepatitis, or NASH, is the most serious form of the disease, and can lead to total liver failure requiring liver transplant. NASH is known as a silent killer because it does not present with many symptoms and those affected generally feel well. Risk factors include obesity, ... Read More

Four Dangerous Diabetes Drugs

Type 2 diabetes is a growing epidemic around the world with an estimated one in 10 adults predicted to be suffering from the disease by 2030, according to the International Diabetes Foundation. Diabetes increases the risk for serious health complications including heart disease, kidney disease, cancer, blindness, dementia and amputations from neuropathy. Many diabetics require medication to help control blood sugar levels. There are dozens of diabetes treatments on the market and more being developed. But these drugs come at a risk. Here are five type 2 diabetes drugs that carry dangerous side effects: Invokana/Invokamet – Known chemically as canagliflozin, Invokana ... Read More